September 9, 2024 08:58 AM EDTUpdated 03:53 PM

Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer, bispecific combo strategy

Lei Lei Wu

News Reporter

Mid-stage clinical trial results show why Merck and Daiichi Sankyo recently moved an antibody-drug conjugate from their $4 billion partnership into Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer, bispecific combo strategy

Lei Lei Wu

News Reporter

Sign up to read this article for free.

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Merck's Eliav Barr on subcutaneous Keytruda, Summit and deal shopping

FDA tells oncology companies how to run multi-regional cancer trials with a US approval in mind

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Boehringer plans NDA filing for pulmonary fibrosis drug following Phase 3 data

Breaking down silos with a new quantitative approach to drug development

Mer­ck, Dai­ichi Sankyo de­tail Phase 2 ADC re­sults in small cell lung can­cer, bis­pe­cif­ic com­bo strat­e­gy

Lei Lei Wu

News Reporter

Sign up to read this article for free.

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Mer­ck­'s Eli­av Barr on sub­cu­ta­neous Keytru­da, Sum­mit and deal shop­ping

FDA tells on­col­o­gy com­pa­nies how to run mul­ti-re­gion­al can­cer tri­als with a US ap­proval in mind

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Boehringer plans NDA fil­ing for pul­monary fi­bro­sis drug fol­low­ing Phase 3 da­ta

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer, bispecific combo strategy

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Merck's Eliav Barr on subcutaneous Keytruda, Summit and deal shopping

FDA tells oncology companies how to run multi-regional cancer trials with a US approval in mind

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Boehringer plans NDA filing for pulmonary fibrosis drug following Phase 3 data

Breaking down silos with a new quantitative approach to drug development